OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study

Inclusion Criteria: Subjects aged 18 or older, male or female of any race with the diagnosis of NDPH meeting International Classification of Headache Disorders (ICHD-2) criteria will be included in the study. The criteria is as follows: A. Persistent headache fulfilling criteria B and C B. Distinct and clearly remembered onset, with pain becoming continuous and unremitting within 24 hours C. Present for \>3 months D. Not better accounted for by another ICHD-3 diagnosis Exclusion Criteria: 1. Those with relevant physical or psychological illness, particularly conditions that might put them at risk if exposed to OnabotulinumtoxinA (myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other neuromuscular disease). 2. Diagnosis of other primary/secondary headache disorder. 3. Psychiatric disorders that could interfere with study participation. 4. Subjects who abuse drugs, including headache treatments and alcohol (DSM IV criteria). 5. Those allergic to compounds similar to the study medication. 6. Those who are pregnant or breastfeeding, or who do not use adequate contraceptive methods. 7. Those who have had any prior exposure to any botulinum toxin serotype.